• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

    24.01 +0.76 (+3.27%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,509,800
    Open 23.42
    Bid (Size) 24.07 (1)
    Ask (Size) 24.13 (2)
    Prev. Close 23.25
    Today's Range 23.02 - 24.48
    52wk Range 10.41 - 138.81
    Shares Outstanding 93,148,652
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    A Peek at Sarepta Therapeutics's Future Earnings
     
    Via Benzinga
    Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results
    From Sarepta Therapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    -80.7%
    -80.7%
    1 Month
    +24.3%
    +24.3%
    3 Month
    +50.9%
    +50.9%
    6 Month
    -62.2%
    -62.2%
    1 Year
    -80.9%
    -80.9%

    More News

    Read More
    Tradr Unleashes 2X Single-Stock Gold ETFs, Reshaping Short-Term Gold Investment Landscape
    Via MarketMinute
    Topics Artificial Intelligence Derivatives ETFs
    Tradr Launches 9 Single-Stock 2X ETFs With First-Of-Its-Kind OpenDoor, Gold And AI Exposure
    Via Benzinga
    Topics Artificial Intelligence ETFs
    Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF
    Via Stocktwits
    Topics ETFs
    What's Going On Sarepta Stock On Wednesday?
    Via Benzinga
    Why Sarepta Therapeutics Stock Is Rising Nearly 5% Premarket
    Via Stocktwits
    Topics Death
    Leap Therapeutics (LPTX) Plummets Over 20% Amidst Profit-Taking and Volatility Ahead of Key Clinical Data
    Via MarketMinute
    Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Taysha Gene Therapies, Canaan, Ondas Holdings And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Topics Stocks
    Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Incannex Healthcare (NASDAQ: IXHL) Braces for Volatility as Q4 Earnings Loom: Options Traders Eye Strategic Plays
    Via MarketMinute
    Topics Artificial Intelligence Earnings
    This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
    Via Benzinga
    The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property
    Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    Expert Outlook: Sarepta Therapeutics Through The Eyes Of 43 Analysts
    Via Benzinga
    Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
    Via FinancialNewsMedia
    Topics Artificial Intelligence Intellectual Property
    2 Beaten-Down Stocks to Avoid Right Now
    Via The Motley Fool
    Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    EXCLUSIVE: August's 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank?
    Via Benzinga
    SRPT Stock Alert: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Sarepta Therapeutics, Inc. Class Action
    From Robbins LLP
    Via GlobeNewswire
    SAREPTA FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Before the August 25th Deadline
    From Bragar Eagel & Squire
    Via GlobeNewswire
    FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
    From Faruqi & Faruqi, LLP
    Via Business Wire
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
    From Pomerantz LLP
    Via GlobeNewswire
    Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SRPT
    Via TheNewswire.com
    Topics Fraud Lawsuit

    Frequently Asked Questions

    Is Sarepta Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Sarepta Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Sarepta Therapeutics, Inc. - Common Stock trade on?
    Sarepta Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Sarepta Therapeutics, Inc. - Common Stock?
    The ticker symbol for Sarepta Therapeutics, Inc. - Common Stock is SRPT on the Nasdaq Stock Market
    What is the current price of Sarepta Therapeutics, Inc. - Common Stock?
    The current price of Sarepta Therapeutics, Inc. - Common Stock is 24.01
    When was Sarepta Therapeutics, Inc. - Common Stock last traded?
    The last trade of Sarepta Therapeutics, Inc. - Common Stock was at 10/31/25 04:00 PM ET
    What is the market capitalization of Sarepta Therapeutics, Inc. - Common Stock?
    The market capitalization of Sarepta Therapeutics, Inc. - Common Stock is 2.24B
    How many shares of Sarepta Therapeutics, Inc. - Common Stock are outstanding?
    Sarepta Therapeutics, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.